IL284210B2 - Compounds that participate in covalent bonds and their uses - Google Patents
Compounds that participate in covalent bonds and their usesInfo
- Publication number
- IL284210B2 IL284210B2 IL284210A IL28421021A IL284210B2 IL 284210 B2 IL284210 B2 IL 284210B2 IL 284210 A IL284210 A IL 284210A IL 28421021 A IL28421021 A IL 28421021A IL 284210 B2 IL284210 B2 IL 284210B2
- Authority
- IL
- Israel
- Prior art keywords
- alkyl
- optionally substituted
- compound
- pharmaceutically acceptable
- tautomer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/504—Pyridazines; Hydrogenated pyridazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862783816P | 2018-12-21 | 2018-12-21 | |
| US201962894493P | 2019-08-30 | 2019-08-30 | |
| US201962930489P | 2019-11-04 | 2019-11-04 | |
| PCT/US2019/068100 WO2020132597A1 (en) | 2018-12-21 | 2019-12-20 | Compounds that participate in cooperative binding and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL284210A IL284210A (en) | 2021-08-31 |
| IL284210B1 IL284210B1 (en) | 2025-01-01 |
| IL284210B2 true IL284210B2 (en) | 2025-05-01 |
Family
ID=71099011
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL284210A IL284210B2 (en) | 2018-12-21 | 2019-12-20 | Compounds that participate in covalent bonds and their uses |
| IL317393A IL317393A (en) | 2018-12-21 | 2019-12-20 | Compounds that participate in covalent bonds and their uses |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL317393A IL317393A (en) | 2018-12-21 | 2019-12-20 | Compounds that participate in covalent bonds and their uses |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20200197391A1 (https=) |
| EP (1) | EP3897644A4 (https=) |
| JP (2) | JP7721052B2 (https=) |
| KR (1) | KR20210116479A (https=) |
| CN (1) | CN113498342A (https=) |
| AU (2) | AU2019401466B2 (https=) |
| BR (1) | BR112021012057A2 (https=) |
| CA (1) | CA3123869A1 (https=) |
| IL (2) | IL284210B2 (https=) |
| MX (2) | MX2021007468A (https=) |
| SA (1) | SA521422304B1 (https=) |
| SG (1) | SG11202106605VA (https=) |
| TW (1) | TW202600561A (https=) |
| WO (1) | WO2020132597A1 (https=) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201629069A (zh) * | 2015-01-09 | 2016-08-16 | 霍普驅動生物科技股份有限公司 | 參與協同結合之化合物及其用途 |
| EP4302834A3 (en) | 2016-07-12 | 2024-07-17 | Revolution Medicines, Inc. | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors |
| JP7240319B2 (ja) | 2017-01-23 | 2023-03-15 | レヴォリューション・メディスンズ，インコーポレイテッド | アロステリックｓｈｐ２阻害剤としての二環式化合物 |
| KR20190110588A (ko) | 2017-01-23 | 2019-09-30 | 레볼루션 메디슨즈, 인크. | 알로스테릭 shp2 억제제로서의 피리딘 화합물 |
| TW201930292A (zh) | 2017-10-12 | 2019-08-01 | 美商銳新醫藥公司 | 作為變構ｓｈｐ２抑制劑的吡啶、吡嗪和三嗪化合物 |
| JP7361693B2 (ja) | 2017-12-15 | 2023-10-16 | レヴォリューション・メディスンズ，インコーポレイテッド | アロステリックｓｈｐ２阻害剤としての多環式化合物 |
| BR112021012057A2 (pt) * | 2018-12-21 | 2021-10-19 | Revolution Medicines, Inc. | Compostos que participam de ligação cooperativa e usos dos mesmos |
| AU2020377925A1 (en) | 2019-11-04 | 2022-05-05 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202132316A (zh) * | 2019-11-04 | 2021-09-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| IL322454A (en) * | 2019-11-04 | 2025-09-01 | Revolution Medicines Inc | ras inhibitors |
| US20210322405A1 (en) * | 2020-04-15 | 2021-10-21 | Washington University | Compositions and methods for treating cancer |
| IL299131A (en) | 2020-06-18 | 2023-02-01 | Revolution Medicines Inc | Methods for delaying, preventing and treating acquired resistance to RAS inhibitors |
| US20250195521A1 (en) | 2020-09-03 | 2025-06-19 | Revolution Medicines, Inc. | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
| CA3194067A1 (en) | 2020-09-15 | 2022-03-24 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2022133037A1 (en) * | 2020-12-17 | 2022-06-23 | Blossomhill Therapeutics, Inc. | Macrocycles and their use |
| CN116635076A (zh) * | 2020-12-17 | 2023-08-22 | 荣山医药股份有限公司 | 大环化合物及其用途 |
| MX2023011608A (es) * | 2021-04-02 | 2023-12-14 | Massachusetts Gen Hospital | Metodos para inhibir ras. |
| US20240217960A1 (en) * | 2021-04-09 | 2024-07-04 | Universität Basel | Triazine derivative as covalent inhibitors of pi3k |
| KR20240017811A (ko) * | 2021-05-05 | 2024-02-08 | 레볼루션 메디슨즈, 인크. | 암의 치료를 위한 ras 억제제 |
| JP2024516450A (ja) | 2021-05-05 | 2024-04-15 | レボリューション メディシンズ インコーポレイテッド | 共有結合性ｒａｓ阻害剤及びその使用 |
| TW202309052A (zh) | 2021-05-05 | 2023-03-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| AU2022281343A1 (en) | 2021-05-25 | 2023-11-30 | Revolution Medicines, Inc. | Methods for inhibiting ras |
| US12280055B2 (en) | 2021-05-27 | 2025-04-22 | Mirati Therapeutics, Inc. | Combination therapies |
| WO2023015559A1 (en) * | 2021-08-13 | 2023-02-16 | Nutshell Biotech (Shanghai) Co., Ltd. | Macrocycle compounds as inhibitors of ras |
| AR126854A1 (es) | 2021-08-27 | 2023-11-22 | Hoffmann La Roche | Compuestos macrocíclicos para el tratamiento de cáncer |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| CN119212994A (zh) | 2021-12-17 | 2024-12-27 | 建新公司 | 作为shp2抑制剂的吡唑并吡嗪化合物 |
| EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| JP2025510572A (ja) | 2022-03-08 | 2025-04-15 | レボリューション メディシンズ インコーポレイテッド | 免疫不応性肺癌を治療するための方法 |
| CN119156393A (zh) * | 2022-04-25 | 2024-12-17 | 翰森生物有限责任公司 | 环状化合物及其制备方法和医药用途 |
| JP2025519199A (ja) | 2022-06-01 | 2025-06-24 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | がんの治療のためのハロインドール大環状化合物 |
| WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| EP4582426A4 (en) * | 2022-09-19 | 2025-12-24 | Adlai Nortye Biopharma Co Ltd | PAN-KRAS INHIBITOR COMPOUND |
| KR20250085767A (ko) | 2022-09-29 | 2025-06-12 | 광조우 조요 파마테크 컴퍼니 리미티드 | 거대고리 유도체 및 이의 적용 |
| WO2024153028A1 (zh) * | 2023-01-20 | 2024-07-25 | 深圳晶蛋生物医药科技有限公司 | 大环类化合物、其药物组合物及其应用 |
| CN120813588A (zh) | 2023-02-14 | 2025-10-17 | 豪夫迈·罗氏有限公司 | 用于治疗癌症的三环化合物 |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| AR132338A1 (es) | 2023-04-07 | 2025-06-18 | Revolution Medicines Inc | Inhibidores de ras |
| CR20250420A (es) | 2023-04-07 | 2025-11-20 | Revolution Medicines Inc | Inhibidores macrocíclicos de ras |
| CN121464140A (zh) | 2023-04-14 | 2026-02-03 | 锐新医药公司 | Ras抑制剂的结晶形式、含有其的组合物及其使用方法 |
| CN121100123A (zh) | 2023-04-14 | 2025-12-09 | 锐新医药公司 | Ras抑制剂的结晶形式 |
| CN116284045A (zh) * | 2023-05-18 | 2023-06-23 | 西南交通大学 | 一种手性吲哚单元取代的四氢异喹啉化合物及其合成方法 |
| KR20260027943A (ko) * | 2023-05-26 | 2026-03-03 | 레볼루션 메디슨즈, 인크. | Ras 억제제 |
| CN116570599B (zh) * | 2023-07-04 | 2023-10-20 | 四川大学华西医院 | Vs6766联合ly3009120的应用及药物组合物 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025090809A1 (en) * | 2023-10-25 | 2025-05-01 | Kumquat Biosciences Inc. | Macrocyclic heterocycles and uses thereof |
| CN117567483B (zh) * | 2023-11-23 | 2025-10-21 | 济南市中心医院 | 一种通过金催化的不对称环加成反应及动力学拆分合成手性氮杂八元环类化合物的方法 |
| WO2025162395A1 (zh) * | 2024-02-01 | 2025-08-07 | 山东先声生物制药有限公司 | 吲哚衍生物作为ras抑制剂及其应用 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025214350A1 (en) * | 2024-04-08 | 2025-10-16 | Sunrise Oncology (Hong Kong) Limited | Macrocyclic compounds as ras inhibitors for the treatment of cancer |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026046393A1 (zh) * | 2024-09-02 | 2026-03-05 | 山东先声再明生物制药有限公司 | 吲哚类衍生物的制备及其应用 |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7601852B2 (en) * | 2006-05-11 | 2009-10-13 | Kosan Biosciences Incorporated | Macrocyclic kinase inhibitors |
| US9119853B2 (en) * | 2010-02-09 | 2015-09-01 | Neurovive Pharmaceutical Ab | Sanglifehrin based compounds |
| PL2710018T3 (pl) * | 2011-05-19 | 2022-04-04 | Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) | Związki makrocykliczne jako inhibitory kinaz białkowych |
| AR091279A1 (es) * | 2012-06-08 | 2015-01-21 | Gilead Sciences Inc | Inhibidores macrociclicos de virus flaviviridae |
| IL269779B2 (en) * | 2017-04-05 | 2026-04-01 | Revolution Medicines Inc | Methods and reagents for the analysis of protein-protein interfaces |
| BR112021012057A2 (pt) * | 2018-12-21 | 2021-10-19 | Revolution Medicines, Inc. | Compostos que participam de ligação cooperativa e usos dos mesmos |
-
2019
- 2019-12-20 BR BR112021012057-2A patent/BR112021012057A2/pt unknown
- 2019-12-20 US US16/723,438 patent/US20200197391A1/en not_active Abandoned
- 2019-12-20 JP JP2021535755A patent/JP7721052B2/ja active Active
- 2019-12-20 KR KR1020217022312A patent/KR20210116479A/ko active Pending
- 2019-12-20 IL IL284210A patent/IL284210B2/en unknown
- 2019-12-20 AU AU2019401466A patent/AU2019401466B2/en active Active
- 2019-12-20 TW TW114110001A patent/TW202600561A/zh unknown
- 2019-12-20 EP EP19901393.9A patent/EP3897644A4/en active Pending
- 2019-12-20 CA CA3123869A patent/CA3123869A1/en active Pending
- 2019-12-20 CN CN201980092760.0A patent/CN113498342A/zh active Pending
- 2019-12-20 IL IL317393A patent/IL317393A/en unknown
- 2019-12-20 SG SG11202106605VA patent/SG11202106605VA/en unknown
- 2019-12-20 WO PCT/US2019/068100 patent/WO2020132597A1/en not_active Ceased
- 2019-12-20 MX MX2021007468A patent/MX2021007468A/es unknown
-
2021
- 2021-06-17 SA SA521422304A patent/SA521422304B1/ar unknown
- 2021-06-18 MX MX2025001810A patent/MX2025001810A/es unknown
-
2023
- 2023-03-16 US US18/184,766 patent/US20240139185A1/en not_active Abandoned
-
2024
- 2024-11-22 JP JP2024203859A patent/JP2025037925A/ja active Pending
-
2025
- 2025-07-16 AU AU2025205500A patent/AU2025205500A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019401466A1 (en) | 2021-07-01 |
| MX2021007468A (es) | 2021-08-05 |
| IL284210A (en) | 2021-08-31 |
| US20240139185A1 (en) | 2024-05-02 |
| KR20210116479A (ko) | 2021-09-27 |
| EP3897644A1 (en) | 2021-10-27 |
| TW202600561A (zh) | 2026-01-01 |
| SG11202106605VA (en) | 2021-07-29 |
| BR112021012057A2 (pt) | 2021-10-19 |
| WO2020132597A8 (en) | 2020-07-16 |
| AU2025205500A1 (en) | 2025-07-31 |
| AU2019401466B2 (en) | 2025-04-24 |
| JP7721052B2 (ja) | 2025-08-12 |
| EP3897644A4 (en) | 2022-09-07 |
| JP2025037925A (ja) | 2025-03-18 |
| SA521422304B1 (ar) | 2023-12-21 |
| IL284210B1 (en) | 2025-01-01 |
| CA3123869A1 (en) | 2020-06-25 |
| IL317393A (en) | 2025-02-01 |
| US20200197391A1 (en) | 2020-06-25 |
| TW202039509A (zh) | 2020-11-01 |
| CN113498342A (zh) | 2021-10-12 |
| MX2025001810A (es) | 2025-03-07 |
| JP2022520154A (ja) | 2022-03-29 |
| WO2020132597A1 (en) | 2020-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240139185A1 (en) | Compounds that participate in cooperative binding and uses thereof | |
| JP7789906B2 (ja) | Ｒａｓ阻害剤 | |
| AU2022270116A1 (en) | Ras inhibitors | |
| EP4656201A2 (en) | Ras inhibitors | |
| EP4463231A1 (en) | Ras inhibitors | |
| AU2022268962A1 (en) | Ras inhibitors for the treatment of cancer | |
| WO2024211712A1 (en) | Condensed macrocyclic compounds as ras inhibitors | |
| AU2024281092A1 (en) | Ras inhibitors | |
| US20240262847A1 (en) | Covalent ras inhibitors and uses thereof | |
| RU2858913C2 (ru) | Соединения, которые участвуют в кооперативном связывании, и их применение | |
| TWI917313B (zh) | 參與協同結合之化合物及其用途 | |
| HK40128485A (en) | Ras inhibitors |